Predictors of metabolic syndrome persistence 1 year after laparoscopic Roux-en-Y gastric bypass

Martini, Francesco; Anty, Rodolphe; Schneck, Anne-Sophie; Casanova, Vincent; Iannelli, Antonio; Gugenheim, Jean

doi:10.1016/j.soard.2015.02.019

Cited by 21 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few studies have analyzed the relationship between bariatric surgery and remission of MetS. In a study performed by Martini et al (2015), 75.8% of patients achieved remission, while 24.2% of patients showed persistence of MetS 1 year after Roux-en-Y gastric bypass. Guilbert et al (2018) observed that the prevalence of MetS decreased from 100 to 6.34% 1 year after Roux-en-Y gastric bypass, and this decrease was still maintained at 2 years.…”

Section: Discussionmentioning

confidence: 99%

Association of Metabolic Syndrome With Prevalence of Obstructive Sleep Apnea and Remission After Sleeve Gastrectomy

Chen

et al. 2021

Front. Physiol.

View full text Add to dashboard Cite

Obesity is an important risk factor for metabolic syndrome and obstructive sleep apnea (OSA). Bariatric surgery has been shown to effectively reduce weight and obesity-related comorbidities. However, the prevalence and severity of OSA in obese patients with different baseline metabolic states and the improvements of OSA after bariatric surgery remain unknown. The main aims of this study were to ascertain the prevalence of OSA in young Chinese obese patients with different metabolic states and to evaluate their respective OSA remission after laparoscopic sleeve gastrectomy. We first performed a cross-sectional study involving 123 metabolically healthy obese patients and 200 metabolically unhealthy obese patients (who had the same age and BMI ranges) to estimate the prevalence of OSA at baseline. Then we performed a retrospective study, which was registered at ClinicalTrials.gov (ref. NCT02653430) of 67 patients who underwent laparoscopic sleeve gastrectomy to evaluate the remission of OSA. Metabolically healthy and unhealthy obese patients had similar apnea-hypopnea index levels (16.6 ± 22.0 vs. 16.7 ± 18.7 events/h, P = 0.512) and prevalence of OSA (66.7% vs. 69.0%, P = 0.662). Male sex, age, waist circumference and lower liver-to-spleen ratio were independent risk factors for OSA. After laparoscopic sleeve gastrectomy, no difference was found in the decrease in body mass index (BMI) change (10.8 ± 4.8 vs. 10.8 ± 3.0 kg/m2, P = 0.996) or the decrease in the apnea-hypopnea index (18.9 ± 24.6 vs. 17.0 ± 24.0 events/h, P = 0.800). The remission of moderate-to-severe OSA was observed in the MHO (36.3%; 54.5–18.2%, P = 0.125) and MUO (32.2%; 66.1–33.9%, P = 0.001) patients. These results suggest that, in patients with obesity, metabolic syndrome does not add extra risk for the prevalence or severity of OSA. Both metabolically healthy and unhealthy obese patients could benefit equally from laparoscopic sleeve gastrectomy in terms of weight loss and obstructive sleep apnea remission.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Metabolic Syndrome With Prevalence of Obstructive Sleep Apnea and Remission After Sleeve Gastrectomy

Chen

et al. 2021

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…For example, RYBG more effectively improves glucose homeostasis in patients who are noninsulin-dependent diabetic and those with a shorter duration of disease [50,51]. Similarly, certain patient populations may have superior outcomes with the earlier use of EBTs.…”

Section: Future Considerationsmentioning

confidence: 99%

Primary endoscopic therapies for obesity and metabolic diseases

Kumbhari

Oberbach

Nimgaonkar³

2015

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Whilst diet, physical exercise, medication and behavioral therapy can support alleviating early weight gain, the development of severe and class 3 obesity (BMI ≥ 35 kg/m 2 and BMI > 40 kg/m 2 , respectively) presents additional challenges that are difficult to overcome through these measures. As such, WLS is considered an effective treatment option for cases of severe obesity, as it achieves a relatively rapid weight reduction that is often maintained long-term, contributing to the remission of several comorbidities [ 5 , 6 , 7 ] and subsequently reducing the mortality rate [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Vitamin D Levels as an Important Predictor for Type 2 Diabetes Mellitus and Weight Regain Post-Sleeve Gastrectomy

et al. 2022

View full text Add to dashboard Cite

Weight Loss Surgery (WLS), including sleeve-gastrectomy (SG), results in significant weight loss and improved metabolic health in severe obesity (BMI ≥ 35 kg/m2). Previous studies suggest post-operative health benefits are impacted by nutrient deficiencies, such as Vitamin D (25(OH)D) deficiency, while it is currently unknown whether nutrient levels may actually predict post-surgery outcomes. As such, this study investigated whether 25(OH)D levels could predict metabolic improvements in patients who underwent SG. Patients with severe obesity (n = 309; 75% female) undergoing SG participated in this ethics-approved, non-randomized retrospective cohort study. Anthropometry, clinical data, 25(OH)D levels and serum markers were collected at baseline, 6-, 12- and 18-months post-surgery. SG surgery resulted in significant improvements in metabolic health at 6- and 12-months post-surgery compared with baseline, as expected. Patients with higher baseline 25(OH)D had significantly lower HbA1c levels post-surgery (p < 0.01) and better post-surgical T2DM outcomes, including reduced weight regain (p < 0.05). Further analysis revealed that baseline 25(OH)D could predict HbA1c levels, weight regain and T2DM remission one-year post-surgery, accounting for 7.5% of HbA1c divergence (p < 0.01). These data highlight that higher circulating 25(OH)D levels are associated with significant metabolic health improvements post-surgery, notably, that such baseline levels are able to predict those who attain T2DM remission. This highlights the importance of 25(OH)D as a predictive biomarker of post-surgery benefits.

show abstract

Predictors of metabolic syndrome persistence 1 year after laparoscopic Roux-en-Y gastric bypass

Cited by 21 publications

References 28 publications

Association of Metabolic Syndrome With Prevalence of Obstructive Sleep Apnea and Remission After Sleeve Gastrectomy

Association of Metabolic Syndrome With Prevalence of Obstructive Sleep Apnea and Remission After Sleeve Gastrectomy

Primary endoscopic therapies for obesity and metabolic diseases

Vitamin D Levels as an Important Predictor for Type 2 Diabetes Mellitus and Weight Regain Post-Sleeve Gastrectomy

Contact Info

Product

Resources

About